ARM makes little difference to cataract surgery outcomes

Article

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Jie Jin Wang and colleagues from the University of Sydney and the Westmead Hospital, New South Wales, Australia re-examined patients with and without ARM who had undergone cataract surgery between 2001 and 2003. They tested visual acuity (VA) and assessed visual and health-related quality of life (HRQoL) using standardized questionnaires (VF-14, SF-12). Preoperative co-morbidity data was collected from medical records. Poor surgical outcomes (VA< 6/12; no improvement in VA; lowest quintile of VF-14, SF-12 scores) were compared in subjects with and without ARM.

A total of 454 patients were followed up for a mean period of 2.8 years. Similar numbers of patients in the ARM and non-ARM groups had VA< 6/12, equating to 80.2% and 88.8%, respectively. Preoperative early ARM was associated with a slightly lower mean VF-14 score. Increasing age and preoperative ocular co-morbidities were associated with all poor outcomes measured.

The results of this study suggest that patients with ARM who have undergone cataract surgery can expect reasonable outcomes over three years.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.